Miglustat Dipharma

Miglustat, the active ingredient in Miglustat Dipharma, is a glucosylceramide synthase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of Gaucher disease type 1 and Niemann‑Pick disease type C in patients requiring disease‑modifying therapy.

GNH USA supplies Miglustat Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets, and our supply chain adheres to stringent GMP standards, providing comprehensive documentation to support import and clinical use.

Miglustat is used as substrate reduction therapy for lysosomal storage disorders, targeting the accumulation of glycosphingolipids. - Gaucher disease type 1: reduces spleen and liver volume, improves hematologic parameters and bone disease. - Niemann‑Pick disease type C: stabilizes neurological progression and may improve quality of life. - Substrate reduction therapy: provides an oral option to manage glycosphingolipid buildup in selected lysosomal storage disorders.

Miglustat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Abdominal pain - Weight loss

Serious or Rare Side Effects: - Severe depression or suicidal thoughts - Acute pancreatitis - Significant elevation of liver enzymes - Peripheral neuropathy

When prescribing Miglustat, clinicians should consider several safety precautions to minimize risk. - Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess mental health: watch for signs of depression or suicidal ideation. - Evaluate pancreatic status: monitor for persistent abdominal pain or pancreatitis. - Adjust dose in renal impairment: use caution and consider dose reduction in patients with reduced clearance. - Avoid in patients with known hypersensitivity to miglustat or its excipients. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Miglustat can interact with other medicines, affecting its absorption or increasing toxicity.

Major Interactions (Avoid): - Co‑administration with other glucosylceramide synthase inhibitors: may increase risk of overlapping adverse effects. - Use with high‑dose vitamin B6 supplements: may diminish miglustat’s therapeutic effect.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce miglustat absorption; separate dosing by at least 2 hours. - Oral contraceptives: miglustat may lower efficacy; consider alternative contraception or monitor closely. - Warfarin: monitor INR as miglustat may affect anticoagulant control.